Oxygen.Delivered where
it's needed most.
Prolong is developing PP-007, an investigational therapy that carries oxygen to brain tissue during and after treatment for acute ischemic stroke.
- Hemoglobin α/β
- Heme
- CO
- PEG
Stroke care today
46.7%of patients treated with clot removal are living independently 90 days later with today's standard of care
Reopening the vessel is not always enough.Even after the occlusion is removed, the downstream vessels and tissue may still be left without oxygen.
PP-007 is small enough to get past the clot
Under 0.01 µm, more than 700 times smaller than a red blood cell, PP-007 can travel through narrowed and partly blocked vessels, including collateral routes.
67.5%of 40 A-LVO patients given PP-007 alongside standard of care in our HEMERA-1 study were living independently 90 days later (mRS 0-2)
Living independently at 90 days
mRS 0–2 · 40 A-LVO patients
Expected with standard of care~46.7%
HEMERA-1, with PP-00767.5%
HEMERA-1 is done. HEMERA-2 is next.
- 2024FDA Fast Track designation for PP-007Regulatory
- 2025HEMERA-1 Phase 1/2 study completeClinical
- 2026FDA Breakthrough Therapy designationRegulatory
- 2027HEMERA-2, a randomized Phase 3 trialPlanned
Latest news
- Apr 30, 2026FDA grants Breakthrough Therapy designation for PP-007 in A-LVO strokeThe designation covers PP-007 in acute ischemic stroke due to anterior large vessel occlusion.News
- Feb 4, 2026HEMERA-1 and the HERMES-24 score at ISC 2026Poster: using 24-hour scores to predict 90-day outcomes in HEMERA-1, toward earlier interim analysis in stroke drug trials.Presentation
- Oct 20, 2025HEMERA-1 final results presented at World Stroke Congress 2025Phase 1/2 results presented in Barcelona.Presentation